| |
Join us on Dec. 7 for a webinar exploring compendia surveillance and Eurofins BioPharma Product Testing’s processes in maintaining compliance. Register now.
|
|
Today’s Big NewsNov 9, 2023 |
|
January 9-10, 2024 | San Francisco, CA
January 16-18, 2024 | Virtual
Scoring for Patients: How Reducing Risk in 2023 Will Change the Fame for Drug Discovery and Development
Register today and Save $450!
|
|
| By Nick Paul Taylor AstraZeneca is buying its way back into the obesity drug gold rush. Months after dropping its own oral GLP-1 agonist, the Big Pharma has agreed to pay Eccogene $185 million for a similar small molecule that it believes can stake a claim to a market targeted by Eli Lilly, Novo Nordisk, Pfizer and others. |
|
|
|
By Angus Liu Cancer drugs constituted about 40% of AstraZeneca's third-quarter revenue. But several key oncology products fell short of analysts’ expectations. |
By Fraiser Kansteiner The FDA has given a green light to Takeda’s Adzynma, the first recombinant protein product as a preventative or on demand enzyme replacement therapy in adults and kids with congenital thrombotic thrombocytopenic purpura. |
By Andrea Park Acutus Medical is planning to cut a majority of its jobs as it narrows its focus to only the most potentially profitable pursuits. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Kevin Dunleavy In 2018, Hutchmed’s fruquintinib became the first domestically developed drug for a major cancer type to be approved in China. Five years later, Takeda has scored an FDA approval for the VEGF inhibitor for adults with metastatic colorectal cancer (mCRC) as a third-line treatment. |
By Andrea Park Owlet is surely flying high after finally securing FDA clearance for its Dream Sock baby monitoring system that alerts parents and other caregivers if a child’s vital signs leave healthy ranges—a feature that previously landed the company in hot water with the regulator. |
By James Waldron By far the most brutal cutbacks were at SQZ, which is letting go of fully 80% of its workforce as the cell therapy company seeks a long-term survival plan. |
By Max Bayer Novavax is looking to shave off an additional $300 million in costs in addition to reductions announced six months ago. The company's R&D and SG&A spend on the year is expected to be roughly 30% lower than in 2022. |
By Zoey Becker While Bayer's PI3K Aliqopa couldn't prove its worth in a confirmatory trial, Novo's Levemir faced manufacturing issues and troubles with patient coverage, leading the two to separately withdraw their products. |
By Gabrielle Masson Adaptimmune Therapeutics, Monte Rosa Therapeutics and Intellia Therapeutics are all throwing programs to the discard pile. |
By Conor Hale As it closes in on its multi-year plan to spur long-term growth by the end of its 2025 fiscal year, BD posted increases in revenues despite the continuing erosion of COVID-19 diagnostic sales. |
Fierce podcastsDon’t miss an episode |
| | While the new Alzheimer’s disease medicine Leqembi has generated lots of buzz since its debut this year, one research team is investigating whether the medicine holds promise in preventing disease progression before any Alzheimer’s symptoms are evident. In this week's episode of "The Top Line," Fierce Pharma’s Eric Sagonowsky talks with the study lead, Reisa Sperling, M.D., to learn more. |
|
|---|
|
|
| WebinarWatch now to explore the convergence of science, capital, operational excellence and workplace strategy. Sponsored by: JLL |
| Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperDownload our whitepaper to learn about plasmid DNA design considerations for cell and gene therapy applications. Sponsored by: Aldevron, a GMP manufacturing CDMO of DNA, RNA, and Proteins |
| WhitepaperThis paper explores AI’s potential impact on healthcare and on Medical Affairs (MA) more specifically. It also outlines what MA teams can do now to proactively leverage AI to improve service to their stakeholders. Presented by Blue Matter, strategic consultants in the life sciences |
| eBookEmulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
| WhitepaperAccelerate drug discovery with high-performance computing (HPC) powered by the cloud Sponsored By: AWS, NVIDIA, and Rescale |
| |
|
